March 2026 - Page 7 of 19

Release – Cardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting

Posted on March 19, 2026March 19, 2026 by [email protected]

March 19, 2026

Preclinical results in therapy-resistant HER2-low breast cancer models demonstrate enhanced antitumor activity and reversal of resistance with PLK1 inhibition

SAN DIEGO, March 19, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that new preclinical data highlighting the potential of its highly specific oral PLK1 inhibitor, onvansertib, in combination with trastuzumab deruxtecan (T-DXd) will be presented at the American Association for Cancer Research Annual Meeting 2026, taking place April 17-22, 2026 in San Diego, California.

The poster presentation will showcase findings demonstrating that onvansertib enhanced the antitumor activity of T-DXd and reversed resistance in therapy-resistant HER2-low breast cancer models.

Poster Presentation Details:

Title: PLK1 inhibitor onvansertib potentiates the antitumor efficacy of trastuzumab deruxtecan (T-DXd) and reverses its resistance in therapy-resistant HER2-low breast cancer models
Date & Time: April 19, 2026 | 2:00 PM – 5:00 PM PT
Abstract Number: 329

The poster will be made available on the Scientific Publications page of the Company’s website following the presentation.

About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor currently in mid-stage clinical development for RAS-mutated metastatic colorectal cancer. It is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML).

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Investor Contact:
Candice Masse
astr partners
[email protected]

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
[email protected]

Release – Nicola Mining Announces The Completion Of The Ubc Master’s Thesis Concluding That Craigmont Is Part Of A Porphyry-Linked Skarn System

Posted on March 19, 2026March 19, 2026 by [email protected]

Research News and Market Data on HUSIF

March 19, 2026

News Releases

VANCOUVER, BC, March 19, 2026 – Nicola Mining Inc. (the “Company” or “Nicola”) (TSX: NIM) (OTCQB: HUSIF) (FSE: HLIA) is pleased to announce that Warren Wagner has completed his Master of Science (M.Sc.) thesis, at the university of British Columba’s (UBC) Mineral Deposit Research Unit (MRDU), on the New Craigmont copper project^[1]. His thesis is titled The Skarn to Porphyry Transition: Establishing Links Between Skarn and Porphyry-Type Mineralization at New Craigmont British Columbia. The full publication and supplementary data tables are available for download on the UBC website: https://open.library.ubc.ca/soa/cIRcle/collections/ubctheses/24/items/1.0451531

The purpose of the thesis was to examine the potential connection between the historically mined Craigmont skarn and undiscovered porphyry systems in the surrounding area. Using field observations, petrography, whole-rock and mineral chemistry, and integrated geochronology, Warren’s thesis has redefined Craigmont as a porphyry-linked skarn system genetically tied to multi-pulsed Late Triassic magmatism within the Guichon Creek batholith’s Border Phase.

Mineral ages determined through geochronology lab work defined two discrete hydrothermal stages: massive calcsilicate skarn alteration at ~215 Ma related to the earliest Border Phase intrusions and overprinting, vein-hosted porphyry-type mineralization at ~209 Ma associated with later, oxidized intrusions.

Potassic, phyllic, calc-potassic, and propylitic alteration styles indicate the presence of a larger porphyry system proximal to the skarn deposit. Epidote mineral chemistry from propylitic assemblages further supports this. New Craigmont epidote contains elevated porphyry indicator trace elements consistent with other porphyry deposits in British Columbia and worldwide. Finally, epidote mineral chemistry systematics within the Guichon Creek batholith reveal that New Craigmont contains a separate, porphyry centre, unrelated to those of the Highland Valley district. The study also highlights the importance of structural permeability and reactive Nicola Group host rocks in focusing hydrothermal fluids and controlling the distribution of skarn and porphyry-style mineralization.

Conclusions of the study have positive implications for ongoing exploration at New Craigmont. The study confirms Nicola’s ongoing hypothesis that the historical skarn is driven by a nearby porphyry system. Detailed geochemistry work has helped narrow exploration to broadly two regions within the property: West Craigmont (where the Draken target is located), and east of the historical mine (where the Jotun target is located). Nicola is integrating MRDU data into ongoing vectoring work and target generation.

Peter Espig, CEO of Nicola, stated, “We applaud Warren and MRDU on two years of fruitful work at our New Craigmont Copper Project. The thesis’ conclusion aligns with our growing confidence in our three years of geological work, mapping and 2025 porphyry vectoring. Given the size of our land package and location, which includes sharing Guichon Batholith with Highland Valley Copper, the prospect of having one or more porphyries at New Craigmont is increasingly compelling, as highlighted in the thesis. We are very encouraged to commence our 2026 Exploration Program.”

Qualified Person

The scientific and technical disclosures included in this news release have been reviewed and approved by Will Whitty, P.Geo., who is the Qualified Person as defined by NI 43-101. Mr. Whitty is Vice President, Exploration for the Company.

About Nicola Mining

Nicola Mining Inc. is a junior mining company listed on the TSX-V Exchange and Frankfurt Exchange that maintains a 100% owned mill and tailings facility, located near Merritt, British Columbia. It has signed Mining and Milling Profit Share Agreements with high-grade BC-based gold projects. Nicola’s fully permitted mill can process both gold and silver mill feed via gravity and flotation processes.

The Company owns 100% of the New Craigmont Project, a property that hosts historical high-grade copper mineralization and covers an area of over 10,800 hectares along the southern end of the Guichon Batholith and is adjacent to Highland Valley Copper, Canada’s largest copper mine. The Company also owns 100% of the Treasure Mountain Property, which includes 30 mineral claims and a mineral lease, spanning an area exceeding 2,200 hectares.

On behalf of the Board of Directors

“Peter Espig”
Peter Espig
CEO & Director

For additional information

Contact: Peter Espig
Phone: (778) 385-1213
Email: [email protected]
URL: www.nicolamining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

[1] Initially disclosed June 29, 2022

Perfect (PERF) – Founder-Led Take-Private Proposal

Posted on March 19, 2026March 19, 2026 by [email protected]

Thursday, March 19, 2026

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Take Private Proposal. Perfect Corp. received a preliminary, non-binding proposal from a consortium led by CEO Alice H. Chang and CyberLink to take the company private at $1.95 per share. The transaction would be funded through rollover equity, company cash, and potential debt. The board intends to form a special committee to evaluate the proposal, and there is no assurance that a transaction will be completed.

Ownership structure supports a high likelihood of completion. The consortium controls approximately 53.4% of shares and 81.2% of voting power. In our view, this significantly increases the likelihood of a transaction, subject to special committee approval.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Star Equity Holdings, Inc. (STRR) – Fourth Quarter 2025 Results

Posted on March 19, 2026March 19, 2026 by [email protected]

Thursday, March 19, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Overview. Star Equity’s fourth quarter and full-year financial results reflect positive momentum and improvement over the prior year quarter, largely driven by the August 2025 merger. Overall, 2025 was a transformational year for Star. The merger strengthened the Company’s operating and financial position and accelerated the growth strategy.

4Q25 Results. Fourth quarter 2025 revenue of $56.8 million rose 69% y-o-y, but was slightly below our $58 million estimate. Adjusted EBITDA increased to $2.2 million versus $0.9 million last year. We had projected $2.3 million. Adjusted net loss was $0.10/sh, compared to adjusted net income of $0.04/sh in 4Q24.

Get the Full Report

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

SelectQuote (SLQT) – Launching Franchise-Based Distribution Channel

Posted on March 19, 2026March 19, 2026 by [email protected]

Thursday, March 19, 2026

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

SelectQuote Local. SelectQuote announced SelectQuote Local, a new franchise model designed to complement its core telephonic insurance distribution platform by offering in-person sales and support. Management indicated the initiative leverages the company’s existing marketing, technology, and carrier relationships, positioning it as a natural extension of the platform rather than a shift in strategy.

Complementary model and TAM expansion. In our view, SelectQuote Local is unlikely to cannibalize the company’s core call center operations, as it targets a distinct subset of consumers who prefer in-person engagement. We believe the company can leverage excess lead flow and brand recognition to support early franchise success without significant incremental marketing investment. Additionally, we expect the in-person model could enhance cross-sell opportunities with Healthcare Services, as local relationships may improve customer engagement and trust.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Kuya Silver (KUYAF) – Driving Mineral Resource Growth

Posted on March 19, 2026March 19, 2026 by [email protected]

Thursday, March 19, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Hans Baldau, Associate Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Kuya Silver is significantly scaling its exploration efforts at Bethania. The company has expanded its fully funded 2026 drill program to approximately 20,000 meters, making it the largest drilling campaign in the project’s history. By combining 10,000 meters of surface and 10,000 meters of underground drilling, Kuya seeks to extend known mineralization near existing operations and test new district scale targets, positioning the project for meaningful resource growth.

High-grade regional targets highlight strong expansion potential. Exploration has identified multiple vein systems beyond the current mine area, with high priority prospects such as Millococha, Tito PH, and Carmelitas demonstrating encouraging grades and geological continuity. These areas, supported by historic artisanal mining and recent sampling, suggest the presence of a broader mineralized system that could materially increase the overall resource base.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

The End of Quarterly Earnings? What the SEC’s Reporting Overhaul Means for Small Caps

Posted on March 19, 2026March 19, 2026 by [email protected]

A regulatory change decades in the making may finally be approaching — and for small and microcap public companies, the implications could be significant.

The Securities and Exchange Commission is preparing a proposal that would make quarterly earnings reporting optional, allowing public companies to instead report financial results twice per year. The proposal, which could be published as early as April, is currently in discussions between the SEC and major stock exchanges regarding how listing rules would need to adjust. Once published, it will enter a public comment period of at least 30 days before the SEC votes on the rule.

SEC Chairman Paul Atkins and President Donald Trump have both voiced support for the shift. Trump first raised the idea during his first term in 2018, arguing that semiannual reporting would reduce short-term thinking and cut the administrative costs burdening public companies. That argument has only gained traction since. The quarterly treadmill — preparing financial statements, coordinating with auditors, hosting earnings calls — runs on a near-constant cycle for CFOs at small public companies, consuming resources that lean teams at microcap firms can ill afford.

For larger companies with dedicated investor relations departments and deep finance teams, quarterly reporting is manageable. For a $200 million market cap company with 50 employees, it can feel like a full-time job. Supporters of the proposed change argue this compliance burden is one of the key reasons why many companies choose to stay private longer — or simply never go public at all. A semiannual reporting structure could lower the bar to entry for the public markets and broaden the investable universe of small and microcap stocks.

The EU and the UK both moved to semiannual mandatory reporting roughly a decade ago. Notably, many companies in both markets continued reporting quarterly by choice — suggesting the market itself can enforce disclosure standards even without a regulatory mandate. That precedent is likely to be a central argument for U.S. adoption.

The opposition is real, however. Critics argue that less frequent disclosures reduce market transparency, create wider informational gaps between company insiders and retail investors, and could increase volatility around the two annual reporting windows. For microcap stocks — where information asymmetry is already higher and trading volumes are lower — a six-month gap between financial updates raises legitimate concerns about price discovery.

There’s also the question of what “optional” really means in practice. Institutional investors and analysts who cover microcap names expect regular data. Companies that choose semiannual reporting may find themselves at a disadvantage in terms of analyst coverage and institutional interest, particularly if peers in the same sector continue reporting quarterly. In other words, the market may continue enforcing the quarterly standard even if the SEC doesn’t.

What’s clear is that this proposal has direct implications for the small and microcap space — more so than for any other segment of the public markets. The cost-benefit calculation is most acute at smaller companies, and the potential to attract more issuers to the public markets is a legitimate upside worth monitoring.

The SEC’s formal proposal is expected to follow soon. For issuers, investors, and advisors in the small and microcap space, the comment period will be the time to shape what this change actually looks like in practice.

Federal Reserve Holds Rates Steady in March 2026 — One Cut Still on the Table as Economy Shows Resilience

Posted on March 19, 2026March 19, 2026 by [email protected]

The Federal Reserve held its benchmark interest rate unchanged Wednesday, keeping the federal funds rate in the range of 3.5% to 3.75% as policymakers assess a shifting economic landscape shaped by elevated energy prices, a resilient growth outlook, and ongoing uncertainty tied to the conflict in the Middle East. The decision marks the second consecutive hold this year, with officials maintaining their projection of one rate cut in 2026 — consistent with guidance issued in December.

The vote was split. Fed Governor Stephen Miran dissented in favor of an immediate quarter-point reduction, reflecting the diversity of views inside the central bank as policymakers weigh competing signals from inflation data, labor markets, and geopolitical developments.

For the first time, the Fed formally acknowledged the war in Iran as an economic variable, stating that “the implications of developments in the Middle East for the U.S. economy are uncertain.” The acknowledgment signals that policymakers are actively monitoring the conflict’s impact on energy prices and supply chains as they assess the timing and pace of future policy adjustments.

Inflation forecasts were revised modestly higher as a result. Officials now see headline inflation at 2.7% for 2026, up from a prior estimate of 2.4%, and core inflation — which excludes food and energy — at 2.7% versus the previous 2.5% projection. While inflation remains above the Fed’s 2% target, the central bank’s updated projections also reflect a more optimistic view of overall economic growth, suggesting policymakers see the current environment as manageable rather than alarming.

In a constructive revision, the Fed raised its GDP growth forecast to 2.4% for 2026, up from 2.3% previously, reflecting continued economic momentum. The unemployment rate projection held steady at 4.4% — a level historically consistent with a healthy labor market.

Month-to-month payroll data has been choppy — January posted a gain of 126,000 jobs followed by a decline of 92,000 in February — but the unemployment rate has remained largely stable throughout the swing, which Fed officials noted as a point of continuity. Policymakers are watching incoming data closely before drawing conclusions about the labor market’s direction.

The Fed’s steady-hand approach offers a degree of predictability that markets and businesses can plan around. With one rate cut still projected for 2026, the path toward monetary easing remains intact — even if the timeline is data-dependent. For small and microcap companies, the key takeaway is that the cost of capital environment, while elevated, appears to be stabilizing rather than tightening further.

The breadth of opinion inside the Fed — ranging from no cuts to as many as four this year — reflects genuine debate rather than consensus pessimism, and leaves room for the policy outlook to shift as energy markets and labor data evolve through the year.

Adding another dimension to the Fed’s near-term story: Chair Jerome Powell’s term expires May 15, and his nominated successor Kevin Warsh awaits Senate confirmation. The transition is unfolding against a complex political backdrop, but the Fed’s institutional framework and data-driven decision-making process are expected to remain intact regardless of timing.

The direction of travel on rates is still lower. The question is when.

Release – Titan International, Inc. Announces Consolidation of Tire Production to Improve Operational Efficiency of US Manufacturing

Posted on March 18, 2026March 18, 2026 by [email protected]

Research News and Market Data on TWI

Mar 18, 2026

WEST CHICAGO, Ill., March 18, 2026 /PRNewswire/ — Titan International, Inc. (NYSE: TWI) (“Titan” or the “Company”), a leading global manufacturer of off-highway wheels, tires, assemblies, and undercarriage products, today announced a decision to consolidate production within its North American manufacturing footprint, which will result in the closure of its manufacturing facility in Jackson, Tennessee by the end of October 2026.

The Company expects production currently performed in Jackson to be transitioned to other existing Titan facilities over the coming months. This action is part of Titan’s ongoing efforts to optimize its manufacturing footprint and improve capacity utilization.

“The decision to consolidate production and close the Jackson facility is difficult knowing the impact it has on our team members and their families,” said Paul Reitz, President and CEO of Titan International. “Titan continues to take deliberate actions to improve its operating efficiency while maintaining the flexibility and scale required to serve our customers.”

The closure of the Jackson, TN facility will impact approximately 140 people and Titan is committed to supporting affected employees through this transition. The Company will work closely with local leadership and provide assistance to impacted team members, including severance, benefits continuation and job placement support. The Company will continue to operate a robust network of manufacturing facilities across North America to support its customers across outdoor power equipment, powersports, agriculture, construction, earthmoving, and other off‑highway end markets.

About Titan: Titan International, Inc. (NYSE: TWI) is a leading global manufacturer of off-highway wheels, tires, assemblies, and undercarriage products. Headquartered in West Chicago, Illinois, the company globally produces a broad range of products to meet the specifications of original equipment manufacturers (OEMs) and aftermarket customers in the agricultural, earthmoving/construction, and consumer markets. For more information, visit www.titan-intl.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/titan-international-inc-announces-consolidation-of-tire-production-to-improve-operational-efficiency-of-us-manufacturing-302717812.html

SOURCE Titan International, Inc.

Release – NN, Inc. Provides Update on Business Growth in the Data Center, AI Reasoning, and Cloud Computing Markets

Posted on March 18, 2026March 18, 2026 by [email protected]

Research News and Market Data on NNBR

PDF Version

CHARLOTTE, N.C., March 18, 2026 (GLOBE NEWSWIRE) — NN, Inc. (“NN” or the “Company”) (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies with six sigma quality, today provided an update on its growing presence in the data center market, a key targeted growth market for the Company.

NN has secured multiple new awards with a leading global provider of AI infrastructure and data center computing equipment. As this industry moves into liquid cooled equipment, it transitions into a natural market for NN. AI reasoning racks are based on an industry-leading chip that requires liquid cooling, and NN has secured liquid cooling positions on these AI reasoning racks which will be installed in the US for AI cloud computing. NN’s existing liquid management products precisely fit the requirements of these applications, and the demanding performance and quality requirements of AI data center and cloud customers are a direct use of the Company’s existing capabilities. Furthermore, next generation computing designs require even higher power use and even higher heat generation, which will lead to next-generation liquid-cooled computing systems and components. The Company can already make products that are advanced beyond today’s requirements. NN has delivered six sigma quality, micron-level tolerance parts for combustion engines for decades. The Company’s decades of global experience and footprint are directly applicable to this new area.

Harold Bevis, President and Chief Executive Officer of NN, Inc., commented, “The liquid-cooled data center market is one of the Company’s new end markets that it is pursuing along with medical, defense and electronics, and electric grid components. The AI data center market fits precisely into NN’s decades of know-how in fluid management and six sigma quality levels. For NN, it is a strategic and straightforward application of existing know-how with managing gas, diesel and hydraulic fluids and applying that know-how to managing cooling fluids. The material science and technical requirements are extremely similar. As we say ‘never leak, never fail’. We have been doing this successfully for decades as a leading global provider of ‘never leak, never fail’ parts that go into vehicle solutions around the world. Our reputation covers billions of parts made over several decades with many customers. We step into this arena as a formidable competitor from Day 1.”

“We have won a multi-year set of awards which is leading NN to invest in a large installation of 17 next-generation high-speed, high-precision CNC machines that will meet and exceed these requirements. This expansion and ramp up is happening now across 2026. These machines will add to NN’s portfolio of over 100 of these similar machines already in-house. We can do this type of production in the US, China, Europe, and South America. This is a gateway strategic win for NN globally. The AI data center expansion for cloud providers is happening globally. This is a multi-billion market that is hyper scaling now, and these computing racks are the hardware behind the expanding use of AI and cloud computing. Financially, these wins fit within NN’s guidance for achieving $70 to $80 million of accretive new business during 2026. These wins contribute to achieving that goal globally.”

“NN is intentionally shifting its business mix into non-automotive, higher-growth, higher-margin markets. The data center AI reasoning computing approaches use a high amount of power and generate a high level of heat. Liquid cooling and cooling fluid management are vital to the success of these approaches, and NN is an expert at handling fluids under these 24/7 operating conditions. The series of wins that NN is announcing today validates that the Company’s capabilities are directly applicable to these customers and this market. ‘Never leak, never fail’. This is precisely the type of accretive, high-value business that we have been intentionally pursuing as part of our ongoing revenue transformation, and we believe it positions NN for a better future with sustained top line growth and continued margin expansion. We are actively prospecting with other AI reasoning and data center equipment providers. Additionally, the fast-charge Electric Vehicle recharging approaches have the same basic issue; they use a lot of power and quickly create a lot of heat, and liquid cooling approaches are coming to this market as well. NN’s products also fit these requirements.”

Rob Esch, NN’s CTO of Machined Parts, said, “Data center and AI infrastructure customers demand above all else precision, reliability, and a supplier with the deep technical know-how to repetitively deliver manufacturing solutions at scale, and that is exactly what NN brings to the table. Our decades of expertise in high-precision machining, six sigma quality, the use of advanced materials, and our well-developed manufacturing methods for precise fluid management give NN a genuine and differentiated capability to serve this market. We can already meet the stringent performance requirements of liquid-cooled computing architectures. As NN builds its capabilities and reputation in this market, we are poised to flex our technical know-how to continue winning next-generation programs with the world’s leading AI hardware developers and hyperscalers. It is a global phenomenon, and we are organized globally for technical product management, and thus we see this happening in multiple markets. It is very exciting and we bring real value to this market and these customers.”

ABOUT NN

NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and China. For more information about the Company and its products, please visit www.nninc.com.

Forward-Looking Statements

This press release contains express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding NN’s pursuit of new end markets, NN’s competitive position in the data center market, the success of NN’s investments to meet the requirements of awarded business, and expected new business wins for 2026 and other statements that are not historical facts. Forward-looking statements generally will be accompanied by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “growth,” “guidance,” “intend,” “may,” “will,” “possible,” “potential,” “predict,” “project”, “trajectory” or other similar words, phrases or expressions. Forward-looking statements involve a number of risks and uncertainties that are outside of management’s control and that may cause actual results to be materially different from such statements. Such factors include, among others, general economic conditions and economic conditions in the industrial sector; material changes in the costs and availability of raw materials; the level of our indebtedness; our ability to secure, maintain or enforce patents or other appropriate protections for our intellectual property; and cyber liability or potential liability for breaches of our or our service providers’ information technology systems or business operations disruptions. The foregoing factors should not be construed as exhaustive and should be read in conjunction with the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in the Company’s filings made with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law. New risks and uncertainties may emerge from time to time, and it is not possible for the Company to predict their occurrence or how they will affect the Company. The Company qualifies all forward-looking statements by these cautionary statements.

Investor Relations:
Joseph Caminiti or Abe Plimpton
[email protected]
312-445-2870

Source: NN, Inc.

Release – GDEV Founder, Chairman and Chief Executive Officer, Andrey Fadeev Increased Ownership Stake to 37%

Posted on March 18, 2026March 18, 2026 by [email protected]

Research News and Market Data on GDEV

March 17, 2026 – Limassol, Cyprus – GDEV Inc. (Nasdaq: GDEV), an international gaming and entertainment company (“GDEV” or the “Company”), today announced that Andrey Fadeev, Chief Executive Officer and Chairman of the Board of Directors, has notified the Company of his purchase of 2,730,384 GDEV ordinary shares from Boris Gertsovskiy, co-founder and former director of the Company, in a private transaction.

Following the transaction, Mr. Fadeev beneficially owns 6,709,391 GDEV ordinary shares, representing 37.0% of the Company’s issued and outstanding shares as of December 31, 2025. Mr. Gertsovskiy has divested himself of the entirety of his remaining shareholding in the Company. At the time of the transaction, Mr. Gertsovskiy did not hold any position of employment (including as a director or officer) at GDEV Inc.

The transaction was conducted by Mr. Fadeev solely in a personal capacity and is not connected with his role as Chief Executive Officer and/or Chairman of the Company. The Company was not a party to the transaction and did not act in concert with Mr. Fadeev in any manner in relation thereto.

About GDEV Inc.

GDEV is a gaming and entertainment holding company, focused on development and growth of its franchise portfolio across various genres and platforms. With a diverse range of subsidiaries including Nexters, Cubic Games, Royal Ark, Game Gears, Light Hour Games among others, GDEV strives to create games that will inspire and engage millions of players for years to come. Its franchises, such as Hero Wars, Island Hoppers, Pixel Gun 3D, Zombie Miner and others have accumulated over 550 million installs and $2.7 billion of bookings worldwide. For more information, please visit www.gdev.inc

Contacts:

Investor Relations
Roman Safiyulin | Chief Corporate Development Officer
[email protected]

Release – Nutriband AI Kinesiology Tapes approved for Distribution and Sale in Costa Rica

Posted on March 18, 2026March 18, 2026 by [email protected]

Research News and Market Data on NTRB

3 hours ago

The Company recently announced an exclusive distribution agreement with Innomedica CCB S.A. for its Kinesiology Line, AVERSA products and Mosquito repellent patches

ORLANDO, Fla., March 18, 2026 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) today announced that The Costa Rica Ministry of Health has approved the Company’s line of Kinesiology Tapes for import and Sale. Innomedica CCB, the company’s exclusive distribution partner for Costa Rica oversaw and financed the regulatory approval process.

The Company, partnering with Innomedica plans to begin ramping up marketing efforts for these products and its mosquito repellant patch line following this latest approval.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband’s AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘’believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Release – PrimeC New Data to Be Presented at AD/PD™ 2026 Conference

Posted on March 18, 2026March 18, 2026 by [email protected]

Research News and Market Data on NRSN

Dr. Christian Lunetta to Present “From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial”

CAMBRIDGE, Mass., March 18, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense”), a late-stage clinical biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases, today announced that Dr. Christian Lunetta will present new data and insights on the development of PrimeC, the company’s investigational therapy for amyotrophic lateral sclerosis (ALS), at the AD/PD™ 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders, to be held in Copenhagen, Denmark, on March 19, 2026.

Dr. Lunetta’s presentation, titled “From PARADIGM to PARAGON: Advancing PrimeC for ALS through Phase 2 Clinical and Biomarker Insights toward a Global Phase 3 Trial,” will take place during the symposium “Mechanisms and Therapeutics in the ALS-FTD Spectrum (SOD-1, TDP-43, C9ORF72 and TMEM106B).”

The presentation will review key clinical and biomarker findings from the Phase 2b PARADIGM trial, which evaluated PrimeC in people living with ALS. The data provide important insights into disease mechanisms and treatment effects that helped inform the design of the company’s global Phase 3 PARAGON trial, currently being advanced to further evaluate PrimeC’s safety and efficacy.

“ALS is one of the most complex neurodegenerative diseases, and advancing therapeutic development requires the integration of rigorous clinical research with deeper biological insight,” said Dr. Christian Lunetta. “The clinical findings emerging from the PARADIGM trial, together with the expanding biomarker analyses, provide an important scientific foundation as we advance toward the PARAGON Phase 3 study. I look forward to sharing these results with the scientific community at AD/PD 2026 and to contributing, together with fellow investigators, to the next stage of clinical development as we work to advance meaningful therapeutic options for people living with ALS.”

“We are deeply appreciative of Dr. Lunetta’s role in presenting these findings and of his contribution as part of the clinical investigator community behind this work,” said Dr. Shiran Zimri, NeuroSense VP of Research and Development and Canada Country Lead. “The timing of this presentation, coming just days after the publication of the PARADIGM results in JAMA Neurology and at such a highly regarded scientific forum, is especially meaningful. It creates a unique moment where robust, peer-reviewed data can immediately be brought into scientific exchange and critical discussion. For us, this is not only about sharing results, but about engaging the field in a deeper understanding of the clinical and biomarker insights from PARADIGM as we advance with urgency toward our global Phase 3 PARAGON study.”

The PARAGON Phase 3 trial is planned as a multinational, randomized, double-blind, placebo-controlled study designed to further evaluate PrimeC’s potential to slow disease progression in people living with ALS.

NeuroSense continues active engagement with regulatory authorities to advance PrimeC toward potential marketing authorization.

About NeuroSense

NeuroSense Therapeutics is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. NeuroSense believes that these diseases, which include amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease, among others, represent one of the most significant unmet medical needs of our time, with limited effective therapeutic options available for patients to date. Due to the complexity of neurodegenerative diseases and based on strong scientific research on a large panel of related biomarkers, NeuroSense’s strategy is to develop combined therapies targeting multiple pathways associated with these diseases.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to synergistically target several key mechanisms of ALS and AD, that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation to potentially inhibit the progression of ALS and AD.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes complete paralysis and death within 2-5 years from diagnosis. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the timing of regulatory filings, meetings and regulatory decisions. Further, certain forward-looking statements, including statements regarding future development of PrimeC, are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward looking statements. These risks include the uncertainty regarding outcomes and the timing of current and future clinical trials; the risk the PrimeC will not advance towards later-stage development, timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; the ability of NeuroSense to remain listed on Nasdaq; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on April 7, 2025 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

Logo: https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg

SOURCE NeuroSense

For further information: For further information: Email: [email protected] | Tel: +972 (0)9 799 6183